Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Paul Covington"'
Autor:
Qiujing Lu, Weiqiao Han, Jeffrey Ling, Minfa Wang, Haoyu Chen, Balakrishnan Varadarajan, Paul Covington
Publikováno v:
2022 International Conference on Robotics and Automation (ICRA).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0effdcb2a98c621484f327c8385956b
https://doi.org/10.1109/icra46639.2022.9812337
https://doi.org/10.1109/icra46639.2022.9812337
Publikováno v:
WSDM
Industrial recommender systems deal with extremely large action spaces -- many millions of items to recommend. Moreover, they need to serve billions of users, who are unique at any point in time, making a complex user state space. Luckily, huge quant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9be48120be6a7395273bba2a98099a53
http://arxiv.org/abs/1812.02353
http://arxiv.org/abs/1812.02353
Publikováno v:
WSDM
The success of recommender systems often depends on their ability to understand and make use of the context of the recommendation request. Significant research has focused on how time, location, interfaces, and a plethora of other contextual features
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::461038cda5d6d6bdac6f7af9377b7e0d
https://doi.org/10.1145/3159652.3159727
https://doi.org/10.1145/3159652.3159727
Publikováno v:
RecSys
YouTube represents one of the largest scale and most sophisticated industrial recommendation systems in existence. In this paper, we describe the system at a high level and focus on the dramatic performance improvements brought by deep learning. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85b8c76d52544ccab339cfa86b333a62
https://doi.org/10.1145/2959100.2959190
https://doi.org/10.1145/2959100.2959190
Autor:
Elisabeth R. Wann, Paul Covington, Penny R. Fleck, Qais Mekki, Michael Davenport, Aziz Karim, Christopher Ronald J
Publikováno v:
Clinical Therapeutics. 30:513-527
Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes.This study was conducted to characterize the pharmacokinetics, pharmacodynamics, and tolerability of single oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f20ea5f5ebaae05595a21ebfdd5242ef
https://doi.org/10.1016/j.clinthera.2008.03.005
https://doi.org/10.1016/j.clinthera.2008.03.005
Autor:
Elisabeth R. Wann, Paul Covington, Michael Davenport, Qais Mekki, Christopher Ronald J, Penny R. Fleck, Aziz Karim
Publikováno v:
Clinical therapeutics. 30(3)
Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes (T2D).This study was conducted to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), and tolerability profi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b24876cc13cbb71d8b0b447f1108b8c
https://pubmed.ncbi.nlm.nih.gov/18405788
https://pubmed.ncbi.nlm.nih.gov/18405788
Publikováno v:
Critical care medicine. 24(1)
Objective To evaluate the safety and efficacy of liposomal prostaglandin E1 (TLC C-53) in the treatment of patients with the acute respiratory distress syndrome (ARDS). Design Randomized, prospective, multicenter, double-blind, placebo-controlled, ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe6bf9f21d27aa76704b16256e926e2
https://pubmed.ncbi.nlm.nih.gov/8565535
https://pubmed.ncbi.nlm.nih.gov/8565535